CASP8 and acute myeloid leukemia: The identification of frequent Caspase-8 mutations in AMLs impairing the response to TRAIL agonistic agents is an important finding that must be carefully evaluated in pre-clinical and clinical studies aiming to induce apoptosis of AML cells through TRAIL-R triggering.